Alembic Pharmaceuticals Ltd: Is It a Deep Value Opportunity?

Alembic Pharmaceuticals Ltd has a deep value score of 35/100 (rated Weak). This score is calculated from three components

• Earnings Score: 21/40 — measures PAT growth momentum across quarters
• Underperformance Score: 14/35 — how much the stock trails Nifty 500 (deeper underperformance = higher contrarian signal)
• Quality Score: 0/25 — operational quality (margins, revenue growth, valuation)

Alembic Pharmaceuticals Ltd's quarterly profit (PAT) growth trajectory

• Latest Quarter PAT Growth (QoQ): +53%
• Previous Quarter PAT Growth (QoQ): -28%
• 2 Quarters Ago PAT Growth (QoQ): +20%
• PAT Acceleration: +16.6pp (profits are accelerating)
• 1 consecutive quarters of positive PAT growth

Alembic Pharmaceuticals Ltd is underperforming the market despite improving earnings — this is the core deep value thesis

• 1-Year Return vs Nifty 500: -26%
• 6-Month Return vs Nifty 500: -14%
• 3-Month Return vs Nifty 500: +6%
• Yet average quarterly PAT growth is +15% — earnings are improving
• The market often takes time to re-rate stocks with improving fundamentals. This gap between price performance and earnings improvement is what deep value research seeks to identify.

Alembic Pharmaceuticals Ltd's earnings momentum is Steady — consistent growth.

• PAT QoQ progression: +20% → -28% → +53% (2Q ago → 1Q ago → latest)
• Acceleration: +16.6pp

Alembic Pharmaceuticals Ltd's valuation metrics

• Price-to-Earnings (PE): 21.4x
• Price-to-Book (PB): 2.5x
• PEG Ratio: 0.0x

Alembic Pharmaceuticals Ltd's revenue and margin trends

• Latest Quarter Revenue Growth (QoQ): -2%
• Average Quarterly Revenue Growth: +3%
• Revenue Acceleration: -6.6pp
• Latest OPM Change: -3.3pp (margins contracting)
• Average OPM Change: -1.4pp

Alembic Pharmaceuticals Ltd key facts

• Sector: Pharma - Formulators
• Market Cap: ₹14.5K Cr
• Rank in Pharma - Formulators: #1 by value score
• Overall rank among all deep value stocks: #100

Alembic Pharmaceuticals Ltd shows limited deep value signals currently — score is 35/100 (Weak). Monitor for improvement.

• Value Score: 35/100 (Weak)
• Earnings: Accelerating
• 1Y Underperformance: -26% vs Nifty 500

Pharma - Formulators deep value sector overview

• 1 deep value stocks in this sector
• Average value score: 35/100
• Avg PAT acceleration: +16.6pp
• Top pick: Alembic Pharmaceuticals Ltd

Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.

The deep value score (0-100) combines three factors:

- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)

Higher score indicates a stronger contrarian research signal.